Changes are coming to embecta Corp.’s Board of Directors.

The company announced that board member David J. Albritton has resigned from the governing body for personal reasons, effective immediately. In addition, Non-Executive Board Chairman LTG (Ret.) David F. Melcher will retire to focus on several commitments beyond his work with the company. Both have been directors since the board’s inception in 2022.

“On behalf of the Board of Directors and the global embecta team, I want to thank both of them for lending their experience, wisdom and guidance as we launched a new company in a dynamic environment,” embecta President/CEO Devdatt “Dev” Kurdikar said. “Each has brought invaluable leadership experience that helped us successfully navigate the unique challenges of separating and standing up embecta. In particular, I wish to thank David Albritton for his contributions in shaping our corporate identity and communications efforts as we worked to establish embecta and provide an unflinching focus on care for people living with diabetes.”

The Board expects to appoint Kurdikar as board chairman, and Dr. Claire Pomeroy—a board member since its inception—as lead independent director, each effective upon Melcher’s departure. The Corporate Governance and Nominating Committee will assess the kind of expertise that may be needed from future independent directors in view of the company’s strategic direction and accordingly recommend any potential replacements for the departing directors.

“I personally have benefited immensely from Dave Melcher’s leadership and mentoring since his appointment as chair of our board,” Kurdikar said. “His counsel and support as we executed multiple complex initiatives in a challenging macroenvironment have been an integral part of our ability to execute all our stand-up programs. I am deeply grateful for Dave’s service and contributions to our company.”

“It has been a privilege to serve as chairman of such a distinguished and collegial Board of Directors,” Melcher stated. “As embecta transitions from its initial standup phase to one where we begin to seed growth, the company’s strategic direction and priorities are clear. I’m confident that the ongoing stewardship of Dev and the rest of the board will enable embecta to continue to prioritize the needs of our customers, employees and shareholders.”

embecta is a global company advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees worldwide.